Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
Public ClinicalTrials.gov record NCT05251727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double-blind, Placebo-controlled, Randomized, Dose-escalating, Multi-center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 With Leucovorin/5-fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
Study identification
- NCT ID
- NCT05251727
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2022 (Actual)
- Primary completion
- Jun 5, 2024 (Actual)
- Completion
- Jun 5, 2024 (Actual)
- Last update posted
- Aug 19, 2024
2022 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beverly Hills Cancer Center | Beverly Hills | California | 90210 | — |
| UCLA Dept. of Medicine - Hematology/Oncology | Los Angeles | California | 90095 | — |
| Eastern Connecticut Hematology & Oncology Associates | Norwich | Connecticut | 06360 | — |
| Mid-Florida Hematology & Oncology Centers | Orange City | Florida | 32763 | — |
| Horizon Oncology Research, Inc. | Lafayette | Indiana | 47905 | — |
| American Oncology Partners, P.A. | Bethesda | Maryland | 20817 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| St. Vincent Frontier Cancer Center | Billings | Montana | 59101 | — |
| Englewood Hospital and Medical Center | Englewood | New Jersey | 07631 | — |
| Site #115 | Hackensack | New Jersey | 07601 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Prisma Health Cancer Institute | Greenville | South Carolina | 29605 | — |
| Nashville Oncology Associates, PC | Nashville | Tennessee | 37203 | — |
| Site #120 | Dallas | Texas | 75230 | — |
| Site #114 | Houston | Texas | 77024 | — |
| MultiCare Regional Cancer Center | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05251727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05251727 live on ClinicalTrials.gov.